Accuracy of Pharmacogenetic Algorithms in Predicting Warfarin Daily Dose

Česká verzia

Authors: A. Tomek ^1,2; T. Kolářová ²; Z. Lacinová ²; S. Martinková ²; M. Šrámek ¹; I. Šarbochová ¹; J. Neumann ³; L. Táborský ²; V. Maťoška ²
Authors place of work: Neurologická klinika 2. LF UK a FN v Motole, Praha ¹; Laboratoř molekulární genetiky, OKBHI, Nemocnice Na Homolce, Praha ²; Neurologické oddělení, Krajská zdravotní, a. s. – Nemocnice Chomutov, o. z. ³
Published in the journal: Cesk Slov Neurol N 2013; 76/109(5): 596-602
Category: Original Paper

Podpora: rezortní program TIP Ministerstva průmyslu a obchodu ČR – FR-TI 1/399.

Summary

Introduction:
Warfarin is used in a wide range of doses and requires frequent INR monitoring with respective dose adjustment. Intra- individual variability of warfarin dose is determined by the individual genotype and CYP2C9 and VKORC1 gene polymorphisms. Pharmacogenetic algorithms could be used to predict the daily dose of warfarin even before the initiation of warfarin treatment.

Aim of study:
To assess frequency of CYP2C9 and VKORC1 polymorphism in the Czech population and to compare empirical daily dose of warfarin with the dose predicted by three previously published pharmacogenetic algorithms.

Methods:
CYP2C9 (alleles *1, *2 and *3) and VKORC1 (haplotypes A and B) genotyping was performed in 1,972 patients. Accuracy of warfarin daily dose prediction was assessed in a cohort of 280 patients with complete relevant clinical data and on a stable dose of warfarin.

Results:
The heterozygous form of the variant genotype of CYP2C9 (reduced warfarin metabolism) was present in 11.6% of patients in our cohort, the homozygous form was found in 1.1%. VKORC1 haplotype A/ A (lower sensitivity for warfarin) was present in 14% of the cohort. Standard expected mean dose of warfarin was used by patients with no (29.2%) or 1 variant allele (41.5%). Coefficients of determination (R²) of the respective assessed algorithms were: Anderson 21.9%, Gage 23.8% and Sconce 58.4%.

Conclusion:
The algorithm by Sconce et al provided the highest agreement between the predicted and empirical daily dose, with 4- fold higher probability that the predicted dose will be ±20% of the empirical dose compared to other assessed algorithms. Pharmacogenetic algorithms were found to be useful in patients of all body weight categories and in patients older than 80 years but not in patients younger than 40 years.

Key words:
warfarin – pharmacogenetics – CYP2C9 protein – VKORC1 protein

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Zdroje

1. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE‑ LY trial. Lancet 2010; 376(9745): 975– 983.

2. Higashi MK, Veenstra DL, Kondo LM, Wittkovsky AK, Srinouanprachanhto SL, Farin FM et al. Association between CYP2C9 genetic variants and anticoagulation‑related outcomes during warfarin therapy. JAMA 2002; 287(13): 1690– 1698.

3. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360(8): 753– 764.

4. Joffe HV, Xu R, Johnson FB, Longtine J, Kucher N,Goldhaber SZ. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91(6): 1123– 1128.

5. Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin patients. Thromb Haemost 2008; 100(2): 229– 239.

6. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353(9154): 717– 719.

7. Margaglione M, Colaizzo D, D’Andrea G, Brancaccio V, Ciampa A, Grandone E et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84(5): 775– 778.

8. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L,King BP et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106(7): 2329– 2333.

9. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352(22): 2285– 2293.

10. Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder M et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005; 77(5): 353– 364.

11. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5(4): 262– 270.

12. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye‑ Anderson A et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358(10): 999– 1008.

13. Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK et al. Influence of CYP2C9 and VKORC1 1173C/ T genotype on the risk of hemorrhagic complications in African‑ American and European‑ American patients on warfarin. Clin Pharmacol Ther 2008; 83(2): 312– 321.

14. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz H et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427(6974): 537– 541.

15. Oldenburg J, Bevans CG, Fregin A, Geisen C, Müller‑ Reible C, Watzka M. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98(3): 570– 578.

16. Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 2011; 57(5): 612– 618.

17. Tomek A, Matoska V, Eisert C, Serebruany VL. Optimization of anticoagulation with warfarin for stroke prevention: pharmacogenetic considerations. Am J Ther 2011; 18(3): e55– e66.

18. Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C,Deych E et al. Genetic‑based dosing in orthopedic patients beginning warfarin therapy. Blood 2007; 110(5): 1511– 1515.

19. Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost 2012; 107(2): 232– 240.

20. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008; 84(3): 326– 331.

21. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP et al. Randomized trial of genotype‑ guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116(22): 2563– 2570.

22. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91(1): 87– 94.

23. Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin Kepoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006; 22(3): 191– 197.

24. Shaw PB, Donovan JL, Tran MT, Lemon SC, Burgwinkle P, Gore J. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J Thromb Thrombolysis 2010; 30(2): 220– 225.